Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
THLD..$4.72 short interest % increases as of Feb 15th. From Jan 31st of 720,533 shares to 1,811,934 on Feb 15th. That is a change of 151.5%
DSCO..$3.70 short interest % increases as of Feb 15th. From Jan 31st of 290,457 shares to 1,071,160 on Feb 15th. That is a change of 268.8%
iBIO DD and Chart:
http://stockcharts.com/c-sc/sc?s=ibio&p=d&yr=0&mn=5&dy=0&id=p74008683657&a=256861803
IBIO: Why I Like this stock and Insider(s)
Hiring of Jules Musing in December
NEWARK, Del., Dec. 7, 2011 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) today announced that Jules A. Musing, an iBio Director, will assume a role as a Managing Director of the Company for at least the next six months in order to accelerate the Company's business development activity. Mr. Musing, formerly a Senior Executive at Johnson & Johnson, joined iBio's Board of Directors in June of 2011. In the course of his career in the Pharmaceutical and Biotechnology Industry, Mr. Musing has been President and Managing Director for Johnson & Johnson, Janssen Pharmaceutica, and Ares Serono companies. At Johnson & Johnson, Mr. Musing was also responsible for worldwide licensing and acquisition of pharmaceutical and biotechnology products and technologies and the establishment of strategic alliances. His activities included the establishment of new scientific and product collaborations in various therapeutic areas, the negotiation of licensing and alliance agreements with biotechnology and pharmaceutical companies worldwide, and the partnering, spin-out and out-licensing of company pharmaceutical and biotechnology assets.
In his role as an iBio Managing Director, Mr. Musing will focus on the Company's business development and licensing activities, including direct dealings with third parties and development of human and material resources to enlarge the Company's business development capacity. "Jules will help us expand our business development capability rapidly to deal with the product candidates already developed on our platform and those we expect in the next few months," said Robert B. Kay, iBio's Chairman and CEO. "We expect Jules' experience as a deal maker and his access to senior management in potential users of our technologies to lead to important business opportunities for us in a variety of U.S. and international markets. We are most fortunate to have his participation during this stage of our growth."
http://www.knobias.com/story.htm?eid=3.1.8a4a7f49d9373801ed4f607aa414e408ef421717541d30ac2d1e940b149d1b3c
MCKEY JOHN D JR whom owned 779.104 added 100,000 shares in January
13-Jan-12 100,000 IBIO Purchase at $0.65 per share.
(Cost of $65,000)
MCKEY JOHN D JR 879,014 Jan 13, 2012
http://biz.yahoo.com/t/00/783.html
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8003032
Eastern Capital 10 million share stake in January taken
13-Jan-12 10,000,000 IBIO Statement of Ownership
http://biz.yahoo.com/t/89/8259.html
iBio listing deficiency resolved January 27, 2012
iBio announced that the NYSE Amex confirmed positive resolution of the company's previously noted listing deficiency with respect to Section 10031i) of the NYSE Amex company guide.
iBIO Market Oppurtunity (click on link)
http://ibioinc.com/home/products/
iBio announces new U.S. patent for iBioLaunch technology
http://finance.yahoo.com/news/iBio-announces-new-U-S-patent-theflyonthewall-413376388.html?x=0&.v=1
and
IBIO Patent Issued on Fusion-Protein Vaccine Technology
Feb. 29, 2012 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) today announced issuance of a US patent covering the use of iBio's proprietary fusion-protein technology in combination with influenza virus antigens for vaccine product applications. The invention comprises the use of lichenase in an adjuvant-like role to improve the performance of vaccines.
Kenneth Dart usually wins also :)
Kenneth recently purchased iBIO his hedge fund, Eastern Capital LTD
Kenneth Dart--SPPI a winner IBIO Soon
Interesting Read
http://caps.fool.com/Blogs/who-is-kenneth-b-dart-and-why/388891
AMRN..$7.53 AMRN 10-K just released. http://bit.ly/x44lX6
This one bounces around like a yo-yo. A definite trader's dream here. Finding the right points of entry are crucial here because this one is so volatile. Closer to the bottom than the top for sure. with a $7.53 price and the 52wk low right near $6.00/share.
$CASM
CASMED to Announce Fourth Quarter Financial Results and Hold Conference Call on March 6, 2012 (pre-market)
http://finance.yahoo.com/news/CORRECTION-CASMED-Announce-pz-2027795589.html?x=0
This news went largely unnoticed:
CASMED's FORE-SIGHT(R) Absolute Tissue Oximeter Gains FDA Clearance for Use on Neonatal Abdomen
http://finance.yahoo.com/news/CASMED-FORE-SIGHT-R-Absolute-pz-1733338478.html
http://finviz.com/quote.ashx?t=casm
PGNX..$9.01 I am still holding as well from $9.55. I might add more if it continues to drop. I still like this one here and their Phase III data is solid! PDUFA date on last week in April. It should move here soon. Good entry here for those not in it, but watch for a bottom first. It may test that tomorrow.
$PBIO CEO putting his money where his mouth is
http://insidercow.com/
$GTXI - This is what I like to see...I added also. This is a rare opportunity to build a position before the Ostarine Phase III data is released later this year.
Ostarine is the drug that prompted an upgrade from Citi to $19/shr. They value this drug alone @ $11/shr!
Who is Jack W. Schuler?
http://people.forbes.com/profile/jack-w-schuler/52535
Enobosarm (OstarineTM, GTx-024), an oral selective androgen receptor modulator, for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer:
http://phx.corporate-ir.net/phoenix.zhtml?c=148196&p=irol-newsArticle&ID=1662984&highlight=
$IBIO - I like that insider buy back in January...interesting play here, thanks.
http://insidercow.com/
IBIO chart shaping up nicely here .87
.78 posted
PGNX..$9.01 being taken to the woodshed on light volume. Still holding.
MarketWatch identifies today's KERX activity as advance speculation on the study
Market Pulse Archives
March 5, 2012, 12:52 p.m. EST
AEterna, Keryx soar on study speculation
AEZS KERX
BOSTON (MarketWatch) -- Shares of Canada's AEterna Zentaris AEZS +20.57% and partner Keryx Biopharmaceuticals KERX +32.16% soared Monday in the wake of an opinion piece on the company that appeared on the investor site Seeking Alpha on Friday. The piece, which was written by a fund manager, said that upcoming Phase III data for the company's cancer-fighting agent Perifosine should be positive, which in turn should drive shares higher. Keryx, which licensed the compound from AEterna, is conducting Phase III trials for the drug in the treatment of colorectal cancer and multiple myeloma. Shares of Keryx shot up 25% to $4.63 as AEterna shares rose 19% to $2.08.
Stimulated http://finviz.com/quote.ashx?t=KERX Me thinks there is part of the 16% short on the float that is covering. I already had sold enough so that my cost basis is now under $2/shr. Since we have 2weeks left it seems strange unless the word/rumor is somehow already out that the stock is acting like this. jmho
THLD Aug'11 - WHY swing plays DO pay off $$$$
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=66043407&txt2find=THLD
KERX--selling more at 5. Big gains today. Lock 'em in!
KERX today is trading 18M shares++ which is nearly 6x the 20MA for volume of 2.14M per day.
If as they say Volume preceeds price then this should be fun to watch. I know it is fun to own.
AMRN..$7.59 so many analysts have their hands in the cookie jar here so the bottom wont completely fall out. Solid trade here imo.
PLX..$5.40 Continues to trade steady here right near the offering price of $5.25 a few wks back. PDUFA date is within two months so I expect it to be trading over $6 soon. Should be a strong catalyst event.
VTUS..$11.05 On high alert here! You posted on this at $9.40 a few weeks ago and it has been on a tear since then. The world of gastrointestinal disorders, hemorrhoids, anal fissures, and fecal incontinence may not be sexy but it is a strong niche that the company wants to dominate.
TLON..$.95 Trading well this week on low volume. Has been trading in a tight range the past few wks. This has the potential to move much higher on any positive news regarding enrollment in the HALLMARQ study or a good Advisory Panel outcome of course.
AEZS..$2.12 Not a good idea to buy here after the SA article last week. Same with KERX. Already up too big here.
Bought PPHM .95 just now on retrace
TRGT with (3) June catalysts this imo should see some momo before too long. *Now we are starting to see the on balance volume level going north, while the accumulation distribution line is stagnant, that many times just is an advance signal of positive demand. jmho
Guess we shall see but this could do well with 2 phase 2 trials and 1 phase 3 in June. BOL
TRGT -
RGEN..$4.70 good news w submission of MAA in EU for Secreflo. Like the priority review status. That is hard to obtain these days for biotech & pharma companies. http://yhoo.it/wYmzTy
KERX---up 25% this AM. Pump and dump from Friday's article? Leaked news? I am taking some profit this AM.
GRVY: Non-consolidated #s out. Very good.
Net income 14.7 mil............3.5xs last years.
HOD @ AEZS ($2.01) +.26/14%
Nice MOMO
GLTA
Investor 100
RGEN:CORRECTING and REPLACING Repligen Announces Submission of Marketing Authorization Application in EU for SecreFlo™ to Improve Pancreatic Imaging in Patients with Pancreatitis
- Follows on U.S. FDA Grant of Priority Review for SecreFlo™ NDA -
Please replace the forward looking statement with the following corrected version.
The corrected release reads:
REPLIGEN ANNOUNCES SUBMISSION OF MARKETING AUTHORIZATION APPLICATION IN EU FOR SECREFLO™ TO IMPROVE PANCREATIC IMAGING IN PATIENTS WITH PANCREATITIS
- Follows on U.S. FDA Grant of Priority Review for SecreFlo™ NDA -
http://finance.yahoo.com/news/repligen-announces-submission-marketing-authorization-120000674.html
Investor 100
ALXA:Alexza to Announce 2011 Year-End Financial Results on Monday, March 12, 2012
Conference Call Scheduled for 5:30 p.m. Eastern Time, March 12, 2012
MOUNTAIN VIEW, Calif., March 5, 2012 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA - News) announced today that it will report results for its fiscal year ended December 31, 2011, on Monday, March 12, 2012, following the close of the U.S. financial markets. On Monday, March 12, at 5:30 p.m. Eastern Time / 2:30 p.m. Pacific Time, the Company will host an investor conference call and live webcast to provide a company update and discuss the financial results. The conference call, live webcast and archived replay are open to all interested parties.
http://finance.yahoo.com/news/alexza-announce-2011-end-financial-140000964.html
Investor 100
$GTXI insiders loading up here...
Director buys 69,700 shares @ $3.33
http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8114561
GRVY: Email from IR dated March 5, 2012.
(Redacted version)
Dear Mr. XXXXXXX
Thank you for your email as always.
As I said in my previous emails, it is true that we are going to issue a press release this week regarding the commercial launch date for RO2.
Thank you for your valuable suggestion but as I also said for several times, the news release for (re)launch Emil Chronicle Online and Requiem on Facebook will be made by Gravity Interactive only when the service is ready.
Kind regards,
Yoon Joo Lee
IR Manager
Gravity Co., Ltd.
Future Link & Business News
http://www.finviz.com/futures.ashx
Greek Bond Swap Deal Rests on Knife Edge
Greece faces a decisive week in its struggle to avert a sovereign default, with a planned debt swap poised on a knife-edge amid doubts over the level of participation by private bondholders.
http://www.cnbc.com/id/46624168
BP reaches settlement in Gulf spill suit
NEW YORK (MarketWatch) — BP PLC said late Friday it has reached a $7.8 billion settlement with a “substantial majority” of the thousands of plaintiffs who sued in the wake of the 2010 Deepwater Horizon oil spill in the Gulf of Mexico.
http://www.marketwatch.com/story/bp-reaches-settlement-in-gulf-spill-suit-2012-03-03?dist=beforebell
Investor 100
ZGNX SA article just out...
http://seekingalpha.com/article/411001-zogenix-smart-biotech-buy-before-earnings
Endocyte to Resume Patient Enrollment in PROCEED Phase 3 Trial in U.S.
This is great news, as there was some concern about even getting a phase 3 study for the European approval this year. This was expressed during the last conference call/ presentation at the end of February.
Moving forward.
gl
Take a look another opinion about $DNDN
http://www.fool.com/investing/general/2012/03/04/this-biotech-drama-queen-is-still-a-buy.aspx
DNDN ---I will be adding shares if we dip below $11. Hoping next few quarters so good sustaining revenue growth. Chances are good IMO.
DNDN..$11.14 Good video about the cost of Provenge for the treatment of prostate cancer as well as some of the benefits of treatment. http://bit.ly/weUGCa
SA about $DNDN
http://seekingalpha.com/article/409421-weekly-stock-watch-feb-27-march-2
Any sign of stability at the current trading levels could be viewed as a positive moving forward, although the lull time between earnings reports also leaves a chance that ten bucks could be revisited.
Thanks for reminding me of that sheff!! Will be doing that today..
OT-Cell Phones# Going Public
Updated Jan 6, 2012
Viral messages warn that a directory of cell phone numbers is about to be published and urge users to dial 888-382-1222 to list mobile numbers with the federal Do Not Call Registry to prevent telemarketing calls.
Analysis: This online rumor has been circulating continuously since September 2004. Despite a very small grain of truth at its core, it's mostly false, outdated, and misleading.
Here's what you need to know:
Yes, you CAN add your cell phone number(s) to the National Do Not Call Registry.
No, you WON'T suddenly be at the mercy of 10,000 telemarketers if you don't.
Contrary to what's claimed, cell phone numbers are NOT about to "go public."
http://urbanlegends.about.com/od/business/a/cell_directory.htm
OT: REMEMBER: Cell Phone Numbers Go Public this month. To prevent this, call the following number from your cell phone: 888-382-1222.
REMINDER..... all cell phone numbers are being released to telemarketing companies and you will start to receive sales calls.
.... YOU WILL BE CHARGED FOR THESE CALLS
It is the National DO NOT CALL list It will only take a minute of your time.. It blocks your number for five (5) years. You must call from the cell phone number you want to have blocked. You cannot call from a different phone number.
OT: Excellent VIDEO..Smartphone pictures pose privacy risks. Great info & tools to make you & your loved ones safer.
just an interesting post to take a note of, and for lazy pontification.
George Soros Portfolio based on feb 14, 2012; 13F filing.
https://ycharts.com/topics/george_soros_portfolio
gl
RGEN..$4.69 Repligen to Present at Cowen and Company Health Care Conference -March 7th 10:40am est http://yhoo.it/x5oEDR
TLON..$.90 I mention in my post that for enrollment of Talon's confirmatory trial that Talon is waiting for a 3rd-6th line patients. The patient population for the confirmatory trial is different than the RALLY study. The Phase 3 study is for patients 60 years or older with newly diagnosed ALL. I wanted to clarify as I was not clear in my earlier message that these are two separate trials. I am still awaiting the first patient enrollment from the HALLMARQ study.
Talon states that the Phase 3 confirmatory trial (Hallmarq) primary objective is:
"To compare overall survival (OS) among subjects 60 years of age and older with newly diagnosed ALL who receive Marqibo versus standard vincristine as a component of multi-agent induction, intensification, and maintenance chemotherapy. The study is powered for superiority."
Follow Me on Twitter: http://twitter.com/SheffStation/
New Economy Portfolio: Larger Cap stocks for slower but more consistent gains. Some Longer-Term Plays (30-60 days maybe longer)
Beginner Portfolio: Scalp Plays & Low Float Biotechs for potential explosive Growth. Quick Turnover 1-30 days (smaller balance want aggressive growth)
Position Size: STARTER: (1-5% Portfolio Balance) SOLID: (6-10% Portfolio Balance) FULL : (11-20% Portfolio Balance)
NEW ECONOMY PORTFOLIO | Sell Date | Ticker | Buy PPS | Sell PPS | Gain/Loss | Notes | % + or - | ||
| |||||||||
|
| ||||||||
|
| | |||||||
|
| ||||||||
|
| | |||||||
|
| | |||||||
| |||||||||
| | ||||||||
Beginner Portfolio Economy | | ||||||||
BUY DATE | SELL DATE | TICKER | BUY PPS | SELL PPS | Gain/Loss | NOTES | % + or - | ||
|
| ||||||||
| | ||||||||
| |||||||||
| |||||||||
| |||||||||
$HEFF LEARNING STATION-LINKS
REAL-TIME Futures Quotes: http://www.sgxniftydowfutureslive.com/index_files/DOWFUTURES.htm …
JANNEY HEALTHCARE NEWSLETTER-http://www.janney.com/institutions--corporations/investment-banking/industry-groups/healthcare/life-sciences-newsletter
Traders: Develop Your Mental Edge by Dr. Andrew Menaker http://j.mp/1phyFIY
Jesse Livermore-Reminiscences Of A Stock Operator-Great Book http://bit.ly/VOObyM
LIFE SCIENCES MARKET : http://www.thelifesciencesreport.com CHMP Decisions Here: http://t.co/7jjqFyn3tx
E-booklet onTrend Determination: A quick accurate and effective methodology using RSI. http://bit.ly/17PmHZ8
The Original Turtle Trading Rules: Rules of the “Turtle Traders;” one of the greatest trading experiments conducted.
http://bit.ly/17jXegf
FAVORITE QUOTES:
"Compounding interest is the eighth wonder of the world. He who understands it, earns it..he who doesn't.. pays it." - Albert Einstein
"Your actions speak so loud I can't hear your words! When that happens, you have found a certain level of success others haven't." Sheff
"IF YOU ARE NOT TAKING YOUR PROFITS, SOMEBODY ELSE IS !" SHEFF
A good name is more desirable than great wealth. Respect is better than silver or gold. -Proverbs 22:1
Don't brag about yourself let others praise you. -Proverbs 27:2
Do not brag about tomorrow, because you do not know what another day may bring. -Proverbs 27:1
One man pretends to be rich, yet has nothing. Another pretends to be poor, yet has great wealth. Proverbs 13:7
You can easily judge the character of a man by how he treats those who can do nothing for him. -James D. Miles
Favorite Sheff Quote: "You can't let praise or criticism get to you. It's a weakness to get caught up in either one." -John Wooden
Favorite Sheff Quote: Talent is God given. Be humble. Fame is man-given. Be grateful. Conceit is self-given. Be careful.
A Trading Plan = Study. A watch-list. Position Sizing. Entries. Exits. Records. Discipline. h/t @sjburns
5 Things I didn't come on twitter to do: Convince anyone of anything , Argue Defend myself Battle Trolls Waste time @sjosephburns
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |